These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12091004)

  • 21. [Kidney protection leads to heart protection, too].
    MMW Fortschr Med; 2006 Aug; 148(33-34):57. PubMed ID: 16981393
    [No Abstract]   [Full Text] [Related]  

  • 22. Effects of losartan in hypertension without vascular disease.
    Messerli FH
    Ann Intern Med; 2004 Apr; 140(7):W29. PubMed ID: 15069010
    [No Abstract]   [Full Text] [Related]  

  • 23. [Hypertension plus left ventricular hypertrophy. Prognosis can now be significantly improved].
    Einecke D
    MMW Fortschr Med; 2002 Apr; 144(14):4-5. PubMed ID: 12014276
    [No Abstract]   [Full Text] [Related]  

  • 24. [A problem that should be recognized. Greater risk of diabetes with antihypertensive drugs?].
    MMW Fortschr Med; 2004 Dec; 146(51-52):50-1. PubMed ID: 15675247
    [No Abstract]   [Full Text] [Related]  

  • 25. The LIFE Trial in 2004.
    Beevers DG
    J Hum Hypertens; 2004 Jun; 18(6):365. PubMed ID: 15153931
    [No Abstract]   [Full Text] [Related]  

  • 26. [Losartan in isolated systolic hypertension--convincing results of a LIFE sub-group study].
    MMW Fortschr Med; 2003 Jan; 145(1-2):50-1. PubMed ID: 12638440
    [No Abstract]   [Full Text] [Related]  

  • 27. [Better prognosis in hypertension and left ventricular hypertrophy. LIFE Study sets new standard].
    MMW Fortschr Med; 2002 May; 144(20):60-1. PubMed ID: 12119887
    [No Abstract]   [Full Text] [Related]  

  • 28. ARB superior to beta blocker in preventing adverse outcomes in older, high-risk hypertensive patients.
    Geriatrics; 2002 May; 57(5):63-4. PubMed ID: 12040595
    [No Abstract]   [Full Text] [Related]  

  • 29. [Study of the efficacy and safety of losartan versus atenolol for aortic dilation in patients with Marfan syndrome].
    Forteza A; Evangelista A; Sánchez V; Teixidó G; García D; Sanz P; Gutiérrez L; Centeno J; Rodríguez-Palomares J; Cortina J; García-Dorado D
    Rev Esp Cardiol; 2011 Jun; 64(6):492-8. PubMed ID: 21561700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Summaries for patients. Benefits of losartan in patients with hypertension and left ventricular hypertrophy but no vascular disease.
    Ann Intern Med; 2003 Aug; 139(3):I28. PubMed ID: 12899605
    [No Abstract]   [Full Text] [Related]  

  • 31. The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
    Fossum E; Moan A; Kjeldsen SE; Devereux RB; Julius S; Snapinn SM; Edelman JM; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Dahlöf B;
    J Am Coll Cardiol; 2005 Sep; 46(5):770-5. PubMed ID: 16139123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Criticism against the atenolol meta-analysis remains].
    Forsén K
    Lakartidningen; 2005 Feb 7-13; 102(6):412, 414; discussion 414-5. PubMed ID: 15754686
    [No Abstract]   [Full Text] [Related]  

  • 33. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K; Hornestam B; Lehto M; Slotwiner DJ; Gerdts E; Olsen MH; Aurup P; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Rokkedal J; Devereux RB
    J Am Coll Cardiol; 2005 Mar; 45(5):705-11. PubMed ID: 15734614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Ruwald AC; Westergaard B; Sehestedt T; Kjeldsen SE; Lindholm LH; Wachtell K; Devereux RB; Ibsen H; Nieminen MS; Dahlöf B; Olsen MH
    J Hypertens; 2012 Jun; 30(6):1252-9. PubMed ID: 22499288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Might losartan reduce sudden cardiac death in diabetic patients with hypertension?
    Aronow WS
    Lancet; 2003 Aug; 362(9384):591-2. PubMed ID: 12944056
    [No Abstract]   [Full Text] [Related]  

  • 38. Angiotensin II inhibition and prevention of atrial fibrillation and stroke.
    Bourassa MG
    J Am Coll Cardiol; 2005 Mar; 45(5):720-1. PubMed ID: 15734616
    [No Abstract]   [Full Text] [Related]  

  • 39. The role of the new beta-blockers in treating cardiovascular disease.
    Weber MA
    Am J Hypertens; 2005 Dec; 18(12 Pt 2):169S-176S. PubMed ID: 16373195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Optimizing antihypertensive therapy. In 5 years 35,000 strokes are preventable].
    MMW Fortschr Med; 2004 Jul; 146(27-28):52. PubMed ID: 15526671
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.